Home / Transcripts / American Vanguard Corporation (AVD) · August 10, 2026

American Vanguard Corporation (AVD) Earnings Call Transcript

August 10, 2026

New York Stock Exchange US Materials Chemicals earnings 24 min

Earnings Call Speaker Segments

Robert Winters executive
#1

Thanks, operator. Hello everyone, and welcome to American Vanguard's Second Quarter 26 Earnings Review Conference Call this afternoon. Our Chief Executive Officer, Dak Kaye, along with our Chief Financial Officer, David T. Johnson, will handle the prepared remarks. After they wrap up, we'll take questions from the line. Today's press release and supplemental slides are available on our website. A replay of the webcast and this event will be posted there shortly once the call ends. Before we begin our presentation, a reminder that today's press release and certain comments made during the call contain non GAAP figures as well as forward looking statements. The outcomes we ultimately see could vary significantly from what's projected here. I'd point you to the forward-looking statements section in our press release and slides, along with the risk factors outlined in the documents we file with the SEC. You can find all of those on our site. At this point, I'm happy to hand things over to our CEO, Dak Kaye.

Douglas A. Kaye executive
#2

Thanks, Bobby, and good morning, everyone — glad to have you with us on the call for our second quarter 26 earnings. The numbers we posted for the quarter and for the first half of this year capture the active, shifting cross currents that are touching agricultural markets and our customers worldwide. What matters even more, though, is how much headway we're achieving when it comes to reducing cost and pushing commercial improvement no matter what the environment throws at us. There are 3 key points I'd like to make today. To start, even with these tough market conditions, we're beating our peers in The US markets. Next, as our business improvement plans get implemented, we're picking up more operating leverage. And third, the money we're putting into new product development is setting up future growth and profitability. When it comes to our effort to reorganize, refocus, and invigorate the commercial push throughout the company, we've made solid progress to this point. What we delivered in the first half of 26 has created the groundwork for opportunities that, in our view, sit both ahead of us and within our control. Before we get into how we performed, let's look at market conditions. During Q2, conditions in the US crop protection sector remained difficult, since multiple simultaneous sources of strain continued to bear down on the agricultural economy. Among them are the cost of capital, which has stayed elevated, along with higher expenses for fuel and fertilizer tied to the ongoing Middle East conflict. When making purchases, distributors, retailers, and growers have remained cautious. Their approach is to buy only what they need, and beyond that, they postpone transactions from one month to the next whenever they can. As a result, order timing is shifting somewhat throughout our operations, in the US and abroad. Another point I'd note is that agriculture markets are under pressure from particular shifts in how consumption is structured and how people behave. This factors in both the years-long drop in total alcohol intake and the rapid rise in GLP 1 medication use, plus how that shift is changing what consumers eat. Outside America, conditions across our overseas markets have proven much tougher. The reasons include bad weather — notably a Super El Nino — as well as inflation-related strain and rising costs for raw materials. Much like what we see with our US markets and customers, our current priority and effort centers on increasing customer engagement while providing strong service and close attention to those we serve. Alongside that, we are accelerating the creation and launch of new products. Our goal is always to serve as a solutions provider for customers, no matter where we connect with them. Let's turn now to the first key point: we are beating our peers across our combined US markets. Net sales for the quarter were down about 10% versus the prior-year period. The biggest factor was softer international sales, which declined 18% during the quarter. US crop sales did fall in the quarter, but that was more than offset by ongoing momentum and expansion in our specialty businesses, where sales grew 11% year over year for the quarter. During the quarter, US crop sales took a hit because of when product sales landed within our cotton product portfolio, with a portion of those sales moving into the third quarter of this year. On the herbicide side, sales came in strong for both the first and second quarters, largely thanks to our brand's impact and Invoke. We keep testing the elasticity of our portfolio in order to drive gross profit dollars and boost manufacturing efficiencies; put simply, demand for our domestic products, which make up our highest margin offerings, remains steady. Turning to our results for the first half of 26: revenue came in at about the same level as a year earlier. Even so, US sales were up 6%, as US crop grew 5% compared with the prior year and specialty sales moved 10% higher. What held back the overall picture was a weaker global backdrop — international sales dropped 13% in the first half of 26 — and that largely canceled out the momentum and above-plan performance we delivered in 2026 up to this point. On to my second key topic: better operating leverage. Gross profit margins for the quarter were down from a year ago, which reflected lower volumes along with the timing of shipments to customers. For the first half of 26, though, gross profit margins improved by 100 basis points, from 29% to 30%, and that was achieved despite revenue being slightly lower. One big cost pressure we faced this quarter and so far this year came from freight expenses running higher. Our estimate is that this cut into margins by about $2.2 million during the first half of 26, which works out to 90 basis points. To offset these increased costs, we've made pricing moves in the market, and we anticipate those efforts will start showing up in our numbers during the second half of 26. On the expense side, if you set aside transformation costs, operating expenses came down 3% compared with the same quarter last year, reflecting our ongoing push for greater efficiency throughout the company. What matters here is that several moves we made during the opening six months of 26 — closing out the LA plant and shifting where our headquarters sits — are going to bring our costs down once we get into the back half of this year. On top of that, we anticipate that transformation costs will come down even more. As a reminder, we believe shutting down the LA production facility will deliver annualized savings of no less than $4 million as we move forward. Put simply, we are holding the line on expenses and staying on top of the items we can actually control, regardless of how market conditions shift. Now let's move to point three, which is about creating the conditions for stronger growth and better profitability by developing new products. One thing that made me really happy was being able to make our leadership group and our sales push even stronger at the start of Q3. That happened when Herman Castro came aboard in early July, taking on the role of senior vice president of marketing and business development. When it comes to our sector, Herman has shown he can lead and deliver results. That's especially true for creating new products and driving innovation. On top of that, we're still putting money into growth down the road, since our spending on R&D climbed 12% compared with the same period last year. As I mentioned before, we've set a goal for ourselves: rolling out 50 products over the next 5 years. By 2030, that work ought to bring in $100 million in annualized revenue. Herman is going to be key to making this program succeed. Right now, I'll stop my comments here and hand things over to David T. Johnson, our CFO, who is going to walk through the quarter's financial results in more depth. Once he's finished, I'll come back to share what we're thinking regarding the 2026 outlook as well as how we expect to grow across the next 2 years. David?

David T. Johnson executive
#3

Thank you, Dak. Hi everybody, and good afternoon. So let's turn to our financial results for the second quarter of 2026. Revenue for the quarter was $117 million, compared with $129 million in the same period of 2025. For the six-month period, sales totaled $240 million, about 2% under the $245 million recorded a year before. US crop sales declined 9% in the quarter. That decline was largely due to the timing of cotton portfolio sales shifting into Q3, as customers are buying closer to the point of use. Insecticide sales were also lower, reflecting light insect pressure as well as growers tightening their spending in key crop markets. Continued momentum in herbicides helped partially offset those decreases. Soil fumigants, in turn, were flat. For the first half, US crop sales were up 5%, supported by herbicide strength through the period, plus granular soil insecticide and cotton insecticide demand concentrated in Q1. Our Specialty business grew 11% in the quarter and 10% in the first half, with gains across a number of market segments. OHP fueled demand for biological solutions, and TER exceeded expectations. International sales were down 18% in the quarter and 13% in the first half. Dry El Nino-related conditions pushed back and reduced usage across Central America. Shipments to certain customers were stopped due to local labor activity; in Mexico, fewer agave acres weighed on herbicide sales; in Brazil, higher pricing dampened demand, stemming from raw material cost increases for our copper fungicide. Gross margin came in at 30% for the quarter, compared with 31% in Q2 of 2025, pressured by a substantial increase in freight costs — about $2 million of impact in the quarter — and, finally, lower overall factory absorption. Despite this Q2 outcome, first-half gross margin improved 100 basis points, ending at 30%, against 29% a year ago. Adjusted EBITDA for the quarter was $600 thousand, down $4.4 million from $11 million in Q2 of 25, driven by lower sales, much higher freight, and weaker manufacturing efficiencies. That was partly offset by better variable cost margins and reduced operating expenses. Year to date, though, adjusted EBITDA climbed by over 20% to $17 million, versus $14 million in the first half of 25. Adjusted operating expenses — excluding items like transformation cost and asset impairment cost — totaled $33.5 million, or 28.5% of sales. This quarter, compared with $34.6 million, or 26.7% of sales, a year ago. On a GAAP basis, expenses declined $1.2 million, with SG&A down approximately $2.1 million, or 7%, partly offset by a 12% rise in research product development and regulatory spending. That reflects the company's focus on new product development. Now to the balance sheet. We closed the quarter with $43.9 million in cash, versus $70.9 million at the close of the first quarter. We finished July with more cash available than we had in June, since quite a few receivables came in during July. Managing cash is still where we’re putting the most attention, since working capital needs typically peak during the second quarter. When the quarter closed, total debt was about $267.6 million, compared with $267 million at the end of the first quarter. Net debt finished the quarter at roughly $224.7 million, versus $194.7 million when the first quarter ended. Adjusted EBITDA for the quarter was $6.6 million, down $4.4 million from $11 million in the second quarter of 2025. Several factors explain that quarter-over-quarter increase in net debt: our accounts payable came back to normal levels, early pay programs at some important customers changed and drove accounts receivable up, and the second quarter brought its typical working capital peak. Inventory came to $181 million, lower than $191 million in the second quarter of last year — a $10 million improvement that reflects tighter production planning and continued working capital discipline. I’ll turn it back to Dak for a few closing comments.

Douglas A. Kaye executive
#4

Thanks, David. Before we start taking questions, I'd like to take a moment to walk investors and all of our stakeholders through where we're focused strategically and what we're aiming for going forward. I've said this on many occasions, and we'll keep saying it: results are what accountability means. For a public company, those results ultimately show up in the numbers; our attention is on growing revenue, getting better utilization out of our higher manufacturing, running more efficiently on operating costs, and bringing overhead down. That translates into stronger gross profit margins, stronger operating margins, and EBITDA that is sustainably higher. Near term, getting our EBITDA margins up into the double digit territory as quickly as we can is the number one priority. As I've mentioned on recent calls, until the agricultural economy improves, our attention stays on what's within our control and on carrying out our strategic business improvement plan, which we believe will let us deliver better adjusted EBITDA than we did in 2025. Our expectation for 2026 remains adjusted EBITDA of $44 million to $48 million, with sales between $530 million and $550 million. Looking at revenue, or the top line, we're anticipating being north of $600 million in annualized run rate revenue by the back half of 28. That's roughly 20% higher than where we were in 2025. Naturally, we'll try to exceed that target, though beating that timing will in all likelihood hinge on how The US and global agricultural markets perform across the next 2 years. The growth we pursue has to be paired with even sharper attention to and gains in our productivity, our efficiency, and our overall cost structure, pushing margins up substantially. Taken together, these things ought to help us produce solid free cash flow, which, combined with lower net working capital, will allow us to bring net debt down across the next 2 years. That puts us in a strong position to refinance our debt. To sum up, despite tough market conditions, we're beating our peers on many fronts. Our operating leverage keeps getting better, and through investment in new products, including additional dedicated staffing, we're laying the groundwork for growth ahead, We recognize there's still plenty of work ahead of us, and the second half of 26 matters a great deal to making 2026 a success. We'll keep assuming that near term, the external environment gives us no help. So we have to control what's ours to control while continuing to execute on our plans for efficiency, growth, and greater profitability. With that, operator, you can open up the call for questions.

Wayne Pinsent analyst
#5

Hello, Dak. I appreciate you fielding my question. I trust everything is going nicely. To kick things off, you mentioned pricing in Mexico, and I think also Latin America. A number of your rivals have discussed growing pressure on pricing in that region. I simply hoped for additional detail regarding what your portfolio is experiencing.

Douglas A. Kaye executive
#6

Yes. The pressure on pricing that we — first of all, Wayne, thank you for asking. Let me begin properly; I didn't intend to cut in there. I appreciate the question. Regarding pricing, what we're observing isn't a reduction. What we're observing is a rise in pricing — in particular, as we noted, the Brazilian market, where 1 of our major offerings is a copper fungicide, and that ties directly to copper LME pricing. So that fundamental raw material expense for the product in Brazil has risen, and it's a fairly elastic product. Consequently, as that cost position climbs for the copper fungicide, demand has fallen correspondingly there. We're observing a rise in pricing worldwide, or in connection with freight. You know, our cost was our cost, and as we noted, it has climbed considerably for freight. Over the last several months, and we're passing that through via new pricing. Here in July. So we're observing price increases, and right now they appear to be sticking.

Wayne Pinsent analyst
#7

All right, that's excellent. I appreciate you clearing that up. And so, you mentioned observing how farmers place orders and purchasing in a more consistent manner. Given those orders that slipped and the fact that you're keeping the guidance for the year intact, how confident are you in the orders? What does the order book look like in terms of tracking and visibility for the remainder of the year?

Douglas A. Kaye executive
#8

Yes. We continue to feel at ease with our projection, and we still believe it is quite attainable. During the second quarter, what we experienced was that certain shipments got delayed in Q2 and pushed into Q3. As a result, the order book looked quite strong entering Q3 compared with what we likely experienced a year ago. That's the reason we feel positive about Q3. and also feel positive about the remainder of the year.

Wayne Pinsent analyst
#9

All right. That's good. Then I'm not sure whether this is the first time you've released it, but regarding those 2028 financial targets and priorities — that double-digit EBITDA growth in 2020 — does that apply to 2027 and 2028? So on an annualized basis, and does it assume some assistance from the market, or does it rest purely on what you believe you're able to control?

Douglas A. Kaye executive
#10

That's a fair question; by the end, by the back half of 28, this is an annualized run rate; those targets are what we expect. We do anticipate seeing some — we do anticipate seeing the correctness in the agricultural market. Should that not happen, we'll make the suitable adjustments to ensure we stay on our course of moving ahead. We do — the ag cycle has been down or in a trough for a long stretch; we do believe that by 2027, 2028, we ought to see some remediation in that cycle; and emerge from it. Yet if it isn't present, we'll keep doing what we're able to do and control our own destiny.

Wayne Pinsent analyst
#11

All right, thanks. And I just want to get some clarity, since you mentioned the run rate for the back half — does that mean it's lower in 2027 and then climbs to double digits during the latter portion of 2028?

Douglas A. Kaye executive
#12

Or would that be double digit on an annualized basis? As we get into the second half of 28, our expectation is an annualized sales rate of $600 million. Oh, okay. But your expectation is double the — oh, sorry. Double-digit EBITDA, however. Right. Double-digit EBITDA. Yes. Double-digit. Okay. Thank you.

Douglas A. Kaye executive
#13

I appreciate all of you making time to join us today. Your backing remains something we deeply appreciate. Here's to a strong 2026 ahead.

Operator operator
#14

That brings us to the end of today's call, so you're free to hang up now. Thanks. For joining us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete American Vanguard Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to American Vanguard Corporation earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.